Short- and long-term outcomes of HIV-infected patients admitted to the intensive care unit: impact of antiretroviral therapy and immunovirological status
Tóm tắt
The purpose of this study was to assess the short- and long-term outcomes of HIV-infected patients admitted to intensive care units (ICU) according to immunovirological status at admission and highly active antiretroviral therapy (HAART) use in ICU. Retrospective study of 98 HIV-infected patients hospitalized between 1997 and 2008 in two medical ICU in Montpellier, France. The primary outcome was mortality in ICU. The secondary end point was probability of survival in the year following ICU admission. Eighty-two (83.6%) admissions in ICU were related to HIV infection and 45% of patients had received HAART before admission. Sixty-two patients (63.3%) were discharged from ICU, and 34 (34.7%) were alive at 1 year. Plasma HIV RNA viral load (VL) and CD4+ cell count separately were not associated with outcome. Independent predictors of ICU mortality were the use of vasopressive agents (odds ratio (OR), 3.779; 95% confidence interval (CI), 1.11–12.861; p = 0.0334) and SAPS II score (OR, 1.04; 95% CI, 1.003-1.077; p = 0.0319), whereas introducing or continuing HAART in ICU was protective (OR, 0.278; 95% CI, 0.082-0.939; p = 0.0393). Factors independently associated with 1-year mortality were immunovirological status with high VL (>3 log10/ml) and low CD4 (<200/mm3; hazard ratio (HR), 5.19; 95% CI, 1.328-20.279; p = 0.0179) or low VL (<3 log10/ml) and low CD4 (HR, 4.714; 95% CI, 1.178-18.867; p = 0.0284) vs. high CD4 and low VL, coinfection with C hepatitis virus (HR, 3.268; 95% CI, 1.29-8.278; p = 0.0125), the use of vasopressive agents (HR, 3.68; 95% CI, 1.394-9.716; p = 0.0085), and SAPS II score (HR, 1.09; 95% CI, 1.057-1.124; p <0.0001). Introducing HAART in a patient with no HAART at admission was associated with a better long-term outcome (HR, 0.166; 95% CI, 0.043-0.642; p = 0.0093). In a population of HIV-infected patients admitted to ICU, short- and long-term outcomes are related to acute illness severity and immunovirological status at admission. Complementary studies are necessary to identify HIV-infected patients who benefit from HAART use in ICU according to immunovirological status and the reasons of ICU admission.
Tài liệu tham khảo
Wachter RM, Luce JM, Turner J, Volberding P, Hopewell PC: Intensive care of patients with the acquired immunodeficiency syndrome. Outcome and changing patterns of utilization. Am Rev Respir Dis 1986, 134: 891–896.
Wachter RM, Russi MB, Bloch DA, Hopewell PC, Luce JM: Pneumocystis carinii pneumonia and respiratory failure in AIDS. Improved outcomes and increased use of intensive care units. Am Rev Respir Dis 1991, 143: 251–256.
Bedos JP, Chastang C, Lucet JC, Kalo T, Gachot B, Wolff M: Early predictors of outcome for HIV patients with neurological failure. JAMA 1995, 273: 35–40. 10.1001/jama.1995.03520250051033
Thyrault M, Gachot B, Chastang C, Souweine B, Timsit JF, Bedos JP, Regnier B, Wolff M: Septic shock in patients with the acquired immunodeficiency syndrome. Intensive Care Med 1997, 23: 1018–1023. 10.1007/s001340050451
Nuesch R, Geigy N, Schaedler E, Battegay M: Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002, 21: 684–687. 10.1007/s10096-002-0792-3
Morris A, Wachter RM, Luce J, Turner J, Huang L: Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003, 17: 73–80. 10.1097/00002030-200301030-00010
Vincent B, Timsit JF, Auburtin M, Schortgen F, Bouadma L, Wolff M, Regnier B: Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era. Intensive Care Med 2004, 30: 859–866. 10.1007/s00134-004-2158-z
Powell K, Davis JL, Morris AM, Chi A, Bensley MR, Huang L: Survival for patients With HIV admitted to the ICU continues to improve in the current era of combination antiretroviral therapy. Chest 2009, 135: 11–17. 10.1378/chest.08-0980
Coquet I, Pavie J, Palmer P, Barbier F, Legriel S, Mayaux J, Molina JM, Schlemmer B, Azoulay E: Survival trends in critically ill HIV-infected patients in the highly active antiretroviral therapy era. Crit Care 2010, 14: R107. 10.1186/cc9056
Huang L, Quartin A, Jones D, Havlir DV: Intensive care of patients with HIV infection. N Engl J Med 2006, 355: 173–181. 10.1056/NEJMra050836
Nickas G, Wachter RM: Outcomes of intensive care for patients with human immunodeficiency virus infection. Arch Intern Med 2000, 160: 541–547. 10.1001/archinte.160.4.541
Afessa B, Green B: Clinical course, prognostic factors, and outcome prediction for HIV patients in the ICU. The PIP (pulmonary complications, ICU support, and prognostic factors in hospitalized patients with HIV) study. Chest 2000, 118: 138–145. 10.1378/chest.118.1.138
Alves C, Nicolas JM, Miro JM, Torres A, Agusti C, Gonzalez J, Rano A, Benito N, Moreno A, Garcia F, et al.: Reappraisal of the aetiology and prognostic factors of severe acute respiratory failure in HIV patients. Eur Respir J 2001, 17: 87–93. 10.1183/09031936.01.17100870
Vargas-Infante YA, Guerrero ML, Ruiz-Palacios GM, Soto-Ramirez LE, Del Rio C, Carranza J, Dominguez-Cherit G, Sierra-Madero JG: Improving outcome of human immunodeficiency virus-infected patients in a Mexican intensive care unit. Arch Med Res 2007, 38: 827–833. 10.1016/j.arcmed.2007.05.007
Morris A, Creasman J, Turner J, Luce JM, Wachter RM, Huang L: Intensive care of human immunodeficiency virus-infected patients during the era of highly active antiretroviral therapy. Am J Respir Crit Care Med 2002, 166: 262–267. 10.1164/rccm.2111025
Narasimhan M, Posner AJ, DePalo VA, Mayo PH, Rosen MJ: Intensive care in patients with HIV infection in the era of highly active antiretroviral therapy. Chest 2004, 125: 1800–1804. 10.1378/chest.125.5.1800
Croda J, Croda MG, Neves A, Dos Santos SD: Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med 2009, 37: 1605–1611. 10.1097/CCM.0b013e31819da8c7
Miller RF, Allen E, Copas A, Singer M, Edwards SG: Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006, 61: 716–721. 10.1136/thx.2005.055905
Dickson SJ, Batson S, Copas AJ, Edwards SG, Singer M, Miller RF: Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy. Thorax 2007, 62: 964–968. 10.1136/thx.2006.072256
Khouli H, Afrasiabi A, Shibli M, Hajal R, Barrett CR, Homel P: Outcome of critically ill human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. J Intensive Care Med 2005, 20: 327–333.
van Lelyveld SF, Wind CM, Mudrikova T, van Leeuwen HJ, de Lange DW, Hoepelman AI: Short- and long-term outcome of HIV-infected patients admitted to the intensive care unit. Eur J Clin Microbiol Infect Dis 2011, 30: 1085–1093. 10.1007/s10096-011-1196-z
Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, Pellegrin JL, Katlama C, Dabis F, Leport C: HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007, 46: 72–77. 10.1097/QAI.0b013e3181576818
Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D: Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection. J Acquir Immune Defic Syndr 2005, 39: 284–292. 10.1097/01.qai.0000160925.33935.72
Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L: Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133: 401–410.
Yeni: French experts group’s recommendations for medical management of HIV infection: highlight and recommendations. 2008.
Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Gunthard HF, Hammer SM, Hirsch MS, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304: 321–333. 10.1001/jama.2010.1004
Casalino E, Wolff M, Ravaud P, Choquet C, Bruneel F, Regnier B: Impact of HAART advent on admission patterns and survival in HIV-infected patients admitted to an intensive care unit. AIDS 2004, 18: 1429–1433. 10.1097/01.aids.0000131301.55204.a7
Morris A, Masur H, Huang L: Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 2006, 34: 42–49. 10.1097/01.CCM.0000194539.50905.81
Zolopa AAJ, Komarow L, et al.: Immediate versus deferred ART in the setting of acute AIDS-related OI: final results of a randomized strategy trial: ACTG A5164. 15th CROI, Boston, MA; 2008. Abstract 142